BACKGROUND: Neither profiles nor prognostic value of cardiac N-terminal proBNP (NT-proBNP) have been prospectively evaluated in a sufficient number of patients with severe chronic heart failure (CHF) treated withcarvedilol or placebo. METHODS:Baseline and follow-up plasma concentrations of NT-proBNP were measured in the European part of the COPERNICUS Trial. This study enrolled patients with an ejection fraction <25% and symptoms of CHF at rest or on minimal exertion, equally randomized toplacebo or carvedilol. RESULTS:NT-proBNP concentrations were increased at baseline (mean+/-S.D.=579+/-822 pmol/l, median=322.5 pmol/l) with a marked decrease during follow-up in the carvedilol, but not in the placebo group. One-year mortality rates were 3.9, 12 and 27.9% in the lower, middle and upper tertiles of NT-proBNP, respectively. When mortality was calculated separately in the placebo and carvedilol group, rates were 0.8, 6.3 and 19.1% in the carvedilol treated but 6.7, 17.9 and 36.9% in the placebo treated patients. CONCLUSIONS:NT-proBNP was a powerful predictor of subsequent all-cause mortality in patients with severe CHF. This marker should therefore be further evaluated for risk stratification and monitoring of therapy in CHF.
RCT Entities:
BACKGROUND: Neither profiles nor prognostic value of cardiac N-terminal proBNP (NT-proBNP) have been prospectively evaluated in a sufficient number of patients with severe chronic heart failure (CHF) treated with carvedilol or placebo. METHODS: Baseline and follow-up plasma concentrations of NT-proBNP were measured in the European part of the COPERNICUS Trial. This study enrolled patients with an ejection fraction <25% and symptoms of CHF at rest or on minimal exertion, equally randomized to placebo or carvedilol. RESULTS: NT-proBNP concentrations were increased at baseline (mean+/-S.D.=579+/-822 pmol/l, median=322.5 pmol/l) with a marked decrease during follow-up in the carvedilol, but not in the placebo group. One-year mortality rates were 3.9, 12 and 27.9% in the lower, middle and upper tertiles of NT-proBNP, respectively. When mortality was calculated separately in the placebo and carvedilol group, rates were 0.8, 6.3 and 19.1% in the carvedilol treated but 6.7, 17.9 and 36.9% in the placebo treated patients. CONCLUSIONS: NT-proBNP was a powerful predictor of subsequent all-cause mortality in patients with severe CHF. This marker should therefore be further evaluated for risk stratification and monitoring of therapy in CHF.
Authors: Kirkwood F Adams; G Michael Felker; Ghassan Fraij; J Herbert Patterson; Christopher M O'Connor Journal: Heart Fail Rev Date: 2010-07 Impact factor: 4.214
Authors: J Malcom O Arnold; Jonathan G Howlett; Paul Dorian; Anique Ducharme; Nadia Giannetti; Haissam Haddad; George A Heckman; Andrew Ignaszewski; Debra Isaac; Philip Jong; Peter Liu; Elizabeth Mann; Robert S McKelvie; Gordon W Moe; John D Parker; Anna M Svendsen; Ross T Tsuyuki; Kelly O'Halloran; Heather J Ross; Vivek Rao; Errol J Sequeira; Michel White Journal: Can J Cardiol Date: 2007-01 Impact factor: 5.223
Authors: Felix Hennig; Alexander V Stepanenko; Hans B Lehmkuhl; Marian Kukucka; Michael Dandel; Thomas Krabatsch; Roland Hetzer; Evgenij V Potapov Journal: Gen Thorac Cardiovasc Surg Date: 2011-01-12
Authors: Stephen J Greene; Robert J Mentz; Mona Fiuzat; Javed Butler; Scott D Solomon; Andrew P Ambrosy; Cyrus Mehta; John R Teerlink; Faiez Zannad; Christopher M O'Connor Journal: Circulation Date: 2018-09-04 Impact factor: 29.690
Authors: Salvatore Di Somma; Laura Magrini; Valerio Pittoni; Rossella Marino; Antonella Mastrantuono; Enrico Ferri; Paola Ballarino; Andrea Semplicini; Giuliano Bertazzoni; Giuseppe Carpinteri; Paolo Mulè; Maria Pazzaglia; Kevin Shah; Alan Maisel; Paul Clopton Journal: Crit Care Date: 2010-06-16 Impact factor: 9.097
Authors: Ian J Neeland; Mark H Drazner; Jarett D Berry; Colby R Ayers; Christopher deFilippi; Stephen L Seliger; Vijay Nambi; Darren K McGuire; Torbjørn Omland; James A de Lemos Journal: J Am Coll Cardiol Date: 2012-12-05 Impact factor: 24.094